{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:26:23Z","timestamp":1789748783806,"version":"4.0.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"vor","delay-in-days":211,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1093\/rap\/rky025","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T13:29:35Z","timestamp":1533043775000},"source":"Crossref","is-referenced-by-count":8,"title":["Outcomes and compliance with standards of care in anti-neutrophil cytoplasmic antibody\u2013associated vasculitis\u2014insights from a large multiregion audit"],"prefix":"10.1093","volume":"2","author":[{"given":"Fiona A","family":"Pearce","sequence":"first","affiliation":[{"name":"Division of Epidemiology and Public Health, University of Nottingham, Nottingham"},{"name":"Department of Rheumatology, Nottingham University Hospitals NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"McGrath","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dudley Group NHS Foundation Trust, Dudley"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dudley Group NHS Foundation Trust, Dudley"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Packham","sequence":"additional","affiliation":[{"name":"Institute of Applied Clinical Science, University of Keele, Newcastle-under-Lyme"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Watts","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ipswich Hospital, Ipswich"},{"name":"Norwich Medical School, University of East Anglia, Norwich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Al-Jayyousi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospitals of Leicester NHS Trust, Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Harper","sequence":"additional","affiliation":[{"name":"Institute of Clinical Sciences, University of Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Obrenovic","sequence":"additional","affiliation":[{"name":"Clinical Audit Department, Dudley Group NHS Foundation Trust, Dudley"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lanyon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nottingham University Hospitals NHS Trust"},{"name":"Department of Rheumatology, Nottingham NHS Treatment Centre, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"2019062610024152900_rky025-B1","volume-title":"Chemotherapy Services in England\u202f: Ensuring Quality and Safety","author":"National Chemotherapy Advisory Group","year":"2009"},{"key":"2019062610024152900_rky025-B2","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2019062610024152900_rky025-B3","volume-title":"Clinical Commissioning Policy: Rituximab for the Treatment of ANCA-Associated Vasculitis in Adults","author":"NHS England","year":"2015"},{"key":"2019062610024152900_rky025-B4","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"2019062610024152900_rky025-B5","article-title":"Chemotherapy dose banding to be rolled out across England","volume":"296","author":"Oswald","year":"2016","journal-title":"Pharm J"},{"key":"2019062610024152900_rky025-B6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"2019062610024152900_rky025-B7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"2019062610024152900_rky025-B8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ndt\/gfs428","article-title":"Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study","volume":"28","author":"Hilhorst","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2019062610024152900_rky025-B9","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","article-title":"Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"30(Suppl 1)","author":"Watts","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2019062610024152900_rky025-B10","author":"Bowman"},{"key":"2019062610024152900_rky025-B11","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/rheumatology\/kew232","article-title":"Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population","volume":"55","author":"Pearce","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2019062610024152900_rky025-B12","author":"Luqmani"},{"key":"2019062610024152900_rky025-B13","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.110276","article-title":"The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis","volume":"38","author":"Merkel","year":"2011","journal-title":"J Rheumatol"},{"key":"2019062610024152900_rky025-B14","first-page":"926","article-title":"The contrasting epidemiology of granulomatosis with polyangiitis (Wegener\u2019s) and microscopic polyangiitis. Rheumatology","volume":"51","author":"Watts","year":"2012","journal-title":"(Oxford)"},{"key":"2019062610024152900_rky025-B15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2019062610024152900_rky025-B16","first-page":"1560","article-title":"Incidence and survival rates in Wegener\u2019s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology","volume":"48","author":"Mohammad","year":"2009","journal-title":"(Oxford)"},{"key":"2019062610024152900_rky025-B17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/rheumatology\/41.5.572","article-title":"Predictors of survival and organ damage in Wegener\u2019s granulomatosis","volume":"41","author":"Koldingsnes","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"2019062610024152900_rky025-B18","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.lpm.2015.02.019","article-title":"Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis","volume":"44","author":"Flossmann","year":"2015","journal-title":"Presse Med"},{"key":"2019062610024152900_rky025-B19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s10067-017-3944-7","article-title":"Long-term outcomes of daily oral vs pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis","volume":"37","author":"La-Crette","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2019062610024152900_rky025-B20","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"de Groot","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2019062610024152900_rky025-B21","volume-title":"The UK Strategy for Rare Diseases","author":"Department of Health","year":"2013"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/2\/2\/rky025\/28866138\/rky025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T14:17:59Z","timestamp":1561558679000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rky025\/5062624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,7,31]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rky025","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018]]},"published":{"date-parts":[[2018]]},"article-number":"rky025"}}